PHARMACEUTICAL MALPRACTICE INJURY

In The News

C.B. Fleet named in lawsuit

Pharmaceutical > Litigation

July 12, 2007

Lynchburg, VA - Authorities said that a Norfolk, Virginia law firm has filed a $10 million lawsuit on Wednesday, May 16, against Lynchburg-based C.B. Fleet Company on behalf of a woman who suffered acute renal failure and other side effects after the use of Fleet Phospho-soda prior to a medical procedure.

Pharmaceutical Overviews

Merck: Officials Ignored Conclusion About Death in Vioxx Trial

Merck officials in 2000 ignored the conclusion of a senior scientist that the COX-2 inhibitor Vioxx -- which the company withdrew from the market last September over safety concerns -- had probably caused the death of a patient in a clinical trial, the New York Times reports. According to several e-mail messages related to Vioxx, Alise Reicin, a vice president for clinical research at Merck, repeatedly asked Edward Scolnick, senior scientist at the company from 1985 until 2002, to revise his position about the death "so that we don't raise concerns." Merck cited the cause of death of the patient, a 73-year-old woman, as "unknown" in later reports to FDA and in a paper published in 2003. In one e-mail message, Scolnick wrote that the trial -- called Advantage -- had "put us in a terrible situation." In e-mail messages sent on April 7, 2001, to Douglas Greene, an executive vice president at Merck Research Laboratories, Scolnick raised concerns that the Advantage trial had no scientific purpose. The Merck marketing department had developed the Advantage trial as a promotional tool to introduce about 600 physicians to Vioxx, according to the Times. "This course is just stupid," Scolnick wrote, adding, "Small marketing studies which are intellectually redundant are extremely dangerous." Jeffrey Lisse, a rheumatologist at the University of Arizona who led the Advantage trial, reported in the 2003 paper that five patients who took Vioxx had experienced heart attacks during the trial, compared with one who took naproxen, a difference with no statistical significance. However, the paper did not mention the cardiac deaths of the 73-year-old woman and two other trial participants, the Times reports.

FenPhen: A Brief Overview

FenPhen, a diet pill, was immediately successful and termed as a miracle drug due to its promising results for patients to easily lose weight. However, between 6-7 million people who took FenPhen became adversely affected by the diet pill as fatal health complications were reported in high number.

Neurotin: A Brief Overview

Over forty states are currently investigating if Neurontin maker Pfizer Corp. illegally marketed the epilepsy drug in the U.S.

More Pharmaceutical Overviews...